Antiangiogenic drugs in ovarian cancer

Ovarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian cancer, the clinical development of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumaran, G C, Jayson, G C, Clamp, A R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634670/
https://www.ncbi.nlm.nih.gov/pubmed/19002176
http://dx.doi.org/10.1038/sj.bjc.6604767
_version_ 1782164139925307392
author Kumaran, G C
Jayson, G C
Clamp, A R
author_facet Kumaran, G C
Jayson, G C
Clamp, A R
author_sort Kumaran, G C
collection PubMed
description Ovarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian cancer, the clinical development of this group of drugs and the toxicities specific to this modality of treatment.
format Text
id pubmed-2634670
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-26346702010-01-13 Antiangiogenic drugs in ovarian cancer Kumaran, G C Jayson, G C Clamp, A R Br J Cancer Minireview Ovarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian cancer, the clinical development of this group of drugs and the toxicities specific to this modality of treatment. Nature Publishing Group 2009-01-13 2008-11-11 /pmc/articles/PMC2634670/ /pubmed/19002176 http://dx.doi.org/10.1038/sj.bjc.6604767 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Minireview
Kumaran, G C
Jayson, G C
Clamp, A R
Antiangiogenic drugs in ovarian cancer
title Antiangiogenic drugs in ovarian cancer
title_full Antiangiogenic drugs in ovarian cancer
title_fullStr Antiangiogenic drugs in ovarian cancer
title_full_unstemmed Antiangiogenic drugs in ovarian cancer
title_short Antiangiogenic drugs in ovarian cancer
title_sort antiangiogenic drugs in ovarian cancer
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634670/
https://www.ncbi.nlm.nih.gov/pubmed/19002176
http://dx.doi.org/10.1038/sj.bjc.6604767
work_keys_str_mv AT kumarangc antiangiogenicdrugsinovariancancer
AT jaysongc antiangiogenicdrugsinovariancancer
AT clampar antiangiogenicdrugsinovariancancer

Ejemplares similares